E. C. de Moel

Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors

E. Rozeman, T. Huizinga, R. Toes, 2018, Cancer Immunology Research.

Is optimising gout treatment the key to closing the mortality gap in gout patients?

T. Huizinga, R. M. ten Brinck, S. van Beest, 2017, Annals of the rheumatic diseases.

Association Between Bone Mineral Density and Autoantibodies in Patients With Rheumatoid Arthritis

C. Allaart, C. Turesson, L. Jacobsson, 2020, Arthritis & rheumatology.

In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response

C. Allaart, T. Huizinga, L. Trouw, 2019, Arthritis Research & Therapy.

Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs

C. Allaart, T. Huizinga, G. Schett, 2019, Arthritis Research & Therapy.

Geo-epidemiology of autoantibodies in rheumatoid arthritis: comparison between four ethnically diverse populations

C. Terao, T. Huizinga, L. Trouw, 2023, Arthritis Research & Therapy.

Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes

C. Allaart, T. Huizinga, L. Trouw, 2018, Arthritis Research & Therapy.

In RA, becoming seronegative over the first year of treatment does not translate to better chances of drug-free remission

Y. Goekoop-Ruiterman, C. Allaart, T. Huizinga, 2018, Annals of the rheumatic diseases.